Satsuma Pharma: STS101 Fails To Meet Statistical Significance On Co-primary Endpoints

Satsuma Pharmaceuticals, Inc. (STSA) announced topline results from its phase 3 EMERGE efficacy trial of STS101 powder as an acute treatment for migraine. The company said topline data from the study did not show statistically significant differences between either dosage strength of STS101 and placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two hours post-administration. STS101 was well-tolerated in the trial.

The company said analysis of EMERGE trial data is ongoing, and it expects to provide a detailed update on its business plans after these analyses are completed.

Headquartered in South San Francisco, California, Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing STS101. Shares of Satsuma Pharma were down 83% in pre-market trade on Thursday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cargill, Inc., a privately held food company, is recalling certain chocolate products containing recalled Jif peanut butter due to the potential for salmonella contamination, the U.S. Food and Drug Administration said. The recall involves 795, 8-ounce boxes of Wilbur brand products, such as Milk and Dark Chocolate Covered Peanut Butter Ritz Crackers, Peanut Butter Meltaways... The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals, Inc.'s Dupixent (dupilumab) to treat eosinophilic esophagitis or EoE, a chronic immune disorder. It is the first FDA approval to treat EoE in adults and pediatric patients 12 years and older weighing at least 40 kilograms. Food products maker J. M. Smucker Co. has recalled select Jif peanut butter products sold in the United States due to potential Salmonella contamination, the U.S. Food and Drug Administration said. The recall involves various creamy, crunchy, natural, no added sugar, and reduced fat peanut butter, among others with lot codes 1274425 - 2140425.
Follow RTT